Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Await Additional Torcetrapib Data Before Advancing CETP Agent

Executive Summary

Merck will await further data regarding Pfizer's terminated HDL/LDL compound torcetrapib/Lipitor before moving forward with its own cholesteryl ester transfer protein inhibitor

You may also be interested in...



Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo

Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug

Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo

Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug

Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest

The failure of Pfizer's torcetrapib need not be the death knell of the cholesteryl ester transfer protein inhibitor class, according to analysis of imaging studies presented at the American College of Cardiology Scientific Sessions, because there are several plausible reasons that the lack of efficacy could be due to molecule-specific problems

Related Content

UsernamePublicRestriction

Register

PS047850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel